The mission of SWOG is to improve the practice of medicine in detecting, preventing, and treating cancer. The SWOG Cancer Control Research Base supports this mission through the development, conduct, analysis, and publication of clinical trials in cancer treatment, control and prevention as well as associated research. On average SWOG manages 50 on-going protocols and recruits 5-15,000 patients or subjects yearly to its trials. Under the direction of the Group Chair, the Associate Chair for Cancer Control and Prevention sets the scientific agenda for cancer control and prevention (CCP) within SWOG, which is implemented within five CCP committees;Prevention, Molecular Epidemiology, Cancer Survivorship, Symptom Management and Quality of Life, and Outcomes and Comparative Effectiveness. Often in partnership one of the eight SWOG disease oriented committees (Breast, Gastrointestinal, Genitourinary, Leukemia, Lung, Lymphoma, Melanoma, and Myeloma). The investigators within CCP develop and conduct research that is relevant, innovative and translatable. Additionally, SWOG manages and supports a large set of biorepositories and the infrastructure to provide these clinically annotated specimens to the research community at large. Further, SWOG will provide a unique resource to the research community through the development of a Cancer Comparative Effectiveness Research Center (CCERC) to provide facilitate the prioritization, design, implementation and translation of prospective comparative effectiveness trials within the NCI cooperative group network. The CCERC will become a model infrastructure within the NIH for leveraging burgeoning opportunities in comparative effectiveness research, including the new Patient Centered Outcomes Research Institute (PCORI) and commercial health insurer's movement towards coverage with evidence development funding models. The SWOG Research Base is partnered with 26 Community Clinical Oncology Programs (CCOP) or Minority Based CCOP and approximately 35% of its total accrual comes from the CCOP program. CCOP physicians play a leadership role within the group structure.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA037429-29S1
Application #
8735363
Study Section
Special Emphasis Panel (ZCA1-SRLB-B (J1))
Program Officer
Minasian, Lori M
Project Start
1983-09-30
Project End
2015-05-31
Budget Start
2013-08-16
Budget End
2014-05-31
Support Year
29
Fiscal Year
2013
Total Cost
$405,248
Indirect Cost
$6,500
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Ng, Maggie C Y; Graff, Mariaelisa; Lu, Yingchang et al. (2017) Discovery and fine-mapping of adiposity loci using high density imputation of genome-wide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium. PLoS Genet 13:e1006719
Winchester, Danyelle A; Till, Cathee; Goodman, Phyllis J et al. (2017) Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. Prostate 77:908-919
Lance, Peter; Alberts, David S; Thompson, Patricia A et al. (2017) Colorectal Adenomas in Participants of the SELECT Randomized Trial of Selenium and Vitamin E for Prostate Cancer Prevention. Cancer Prev Res (Phila) 10:45-54
Platz, Elizabeth A; Kulac, Ibrahim; Barber, John R et al. (2017) A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. Cancer Epidemiol Biomarkers Prev 26:1549-1557
Miles, Fayth L; Goodman, Phyllis J; Tangen, Catherine et al. (2017) Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial. Nutrients 9:
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Zhang, X; Schmitt, F A; Caban-Holt, A M et al. (2017) Diabetes mitigates the role of memory complaint in predicting dementia risk: Results from the Prevention of Alzheimer's Disease with Vitamin E and Selenium Study. J Prev Alzheimers Dis 4:143-148
Kryscio, Richard J; Abner, Erin L; Caban-Holt, Allison et al. (2017) Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE). JAMA Neurol 74:567-573
Chen, Haitao; Liu, Xu; Brendler, Charles B et al. (2016) Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial. Prostate 76:1120-9
Murtola, Teemu J; Gurel, Bora; Umbehr, Martin et al. (2016) Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 25:463-9

Showing the most recent 10 out of 362 publications